# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001493152-22-024146
Filing Date
2022-08-26
Accepted
2022-08-26 14:48:23
Documents
5
Period of Report
2022-08-26

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 |  | formdef14a.htm | DEF 14A | 717224
2 |  | def14a_001.jpg | GRAPHIC | 465942
3 |  | def14a_002.jpg | GRAPHIC | 340651
4 |  | def14a_003.jpg | GRAPHIC | 304715
5 |  | def14a_004.jpg | GRAPHIC | 243536
| Complete submission text file | 0001493152-22-024146.txt |  | 2583642

Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

EIN.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39717 | Film No.: 221204436
SIC: 2834 Pharmaceutical Preparations